Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Corporate Update (July 2023)
13 slides from Faron Pharmaceuticals Oy's corporate update, Jul 19, 2023
Slide 1: A CLEVER Approach to Fight Cancer: BEXMAB study update
A CLEVER Approach to Fight Cancer Faron Pharmaceuticals BEXMAB study update 19 July 2023 London A IM: FA RN Helsinki First North: FA RON Faron Pharmaceuticals | Non-Confidential Information
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: Harnessing the Power of Macrophages to Conquer Immune Resistance
Harnessing the Power of Macrophages to Conquer Immune Resistance CLEVER approach to sensitizing cancers to standard of care Bexmarilimab is a humanized function blocking monoclonal antibody to Clever-1 and primes the immune system to attack tumors Clever-1 is an immunosuppressive receptor on macroph
Slide 4: Dual Mode of Action in Hematological Malignancies
Dual Mode of Action in Hematological Malignancies Clever-1 expressed on monocytes and myeloid cells and is abundant in AML Binds directly to Activates monocytes bexmarilimab myeloid cells and in circulation lowers viability Ylitalo et al (2023) Presented AACR AML in Austin 4 FARON PHARMACEUTICALS |
Slide 5: Increase in Antigen Presentation and T Cell Activity Observed
Increase in Antigen Presentation and T Cell Activity Observed Bexmarilimab treatment results in immune activation in bone marrow at tested dose levels* Increase of T and NK cells in the BM of patients during Upregulation of Antigen-presentation treatment across dose levels molecules on blasts during
Slide 6: BEXMAB Phase 1/2 Study Evaluating Bexmarilimab with SoC
BEXMAB Phase 1/2 Study Evaluating Bexmarilimab with SoC Enrichment cohorts of DOUBLET ongoing Dose Finding (Phase 1) Efficacy Evaluation (Phase 2) POPULATION DOUBLET MDS MDS Phase 2 azacitidine + doses r/r AML r/r AML bexmarilimab MDS failing on HMA based therapy MDS HMA failure POPULATION TRIPLET P
Slide 7: Three Objective Responses Observed in the Latest Dosing Cohort
Three Objective Responses Observed in the Latest Dosing Cohort BEXMAB Doublet, 6 mg/kg dosing cohort 7 | 07.19.23
Slide 8: Responses Observed Across Indications and Dose Levels
Responses Observed Across Indications and Dose Levels BEXMAB Doublet, data cut-of 12 July 2023 Complete blood count recovery IDH2 mutation, transfered to other study C6 Allo-HSCT PD 50% reduction of blasts HI-P in cycle 3 8 | 07.19.23
Slide 9: Best Change in Bone Marrow Blasts (%)
9 | 07.19.23 Best Change in Bone Marrow Blasts (%) 1.0 mg/kg 6.0 mg/kg 3.0 mg/kg 3.0 mg/kg 1.0 mg/kg 6.0 mg/kg 3.0 mg/kg 3.0 mg/kg 6.0 mg/kg 6.0 mg/kg 6.0 mg/kg 1.0 mg/kg 3.0 mg/kg 1.0 mg/kg BEXMAB Doublet, data cut-off 12 July 2023 1.0 mg/kg Reduction of Bone Marrow Blasts in Majority of Patients
Slide 10: Bexmarilimab Related Adverse Events
Bexmarilimab Related Adverse Events BEXMAB Doublet, data cut-off 12 July 2023 # AEs (%) Treatment-Related Treatment-Related Adverse Events Grade 1/2 Grade ≥ 3 n=96 Adverse Events Any grade 8 (8) Capillary Leak Syndrome 0 (0) 1 (1) Grade 3 1 (1) Constipation 3 (3) 0 (0) Grade 5 1 (1) Hemoph
Slide 11: Conclusion
Conclusion ➢ Three of five patients in the 6 mg/kg bexmarilimab + azacitidine doublet cohort achieved objective responses (CR and mCR) ➢ Eight of 15 objective responses (ORs) observed across the three dosing doublet cohorts ➢ One patient has stayed on treatment for 13 months ➢ Phase II/III developme
Slide 12: BEXMAB – Accelerated Development Plan for r/r AML/MDS HMA
BEXMAB – Accelerated Development Plan for r/r AML/MDS HMA Aiming to File BLA H1/2025 2023 2024 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Phase I – Dose Escalation Phase II – Dose Phase II – Pivotal, BLA & Confirmatory Expansion Efficacy MDS with failure to HMA Confirmatory Trial (n=x) Expa
Slide 13: Q&A Session
Q&A Session
Faron Pharmaceuticals Oy — Corporate Update (July 2023) on 6ix